VarmX: Valuation, Funding & Investors
VarmX is a biotechnology company based in Leiden, the Netherlands, specializing in the development of innovative therapies for patients on direct oral anticoagulants targeting activated Factor Xa and those with inherited coagulation disorders. The company's lead product, VMX-C001, is designed to bypass the anticoagulation effects of Factor Xa inhibitors, rapidly restoring coagulation in patients experiencing severe bleeding or requiring urgent surgery. VarmX's efforts address a significant unmet need in emergency care, with no fully approved therapeutic agents currently available in the E.U. or the U.S. for such conditions.
Leadership & Board
Latest Estimated Valuation
- Total Amount Raised
- $117M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $117M
- Latest Funding Round
- Series B
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 16, 2025 | Series B | $117.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| EQT Life Sciences | Series B |
| InnovationQuarter | Series B |
| Ysios Capital | Series B |
| EIC | Series B |
| Sound Bioventures | Series B |
| Inkef | Series B |
| Lundbeckfonden BioCapital | Series B |
| BioGeneration Ventures | Series B |
Similar Companies
A snapshot of private companies similar to VarmX, helping you discover and navigate related company profiles.








